Increase in mortality rate in patients with dementia treated with atypical antipsychotics: A cohort study in outpatients in Central Italy

Rivista di Psichiatria

Volumn 49, Issue 1, 2014, Pages 34-40

  Piersanti, Monica ^a   Capannolo, Marta ^b   Turchetti, Maurizio ^a   Serroni, Nicola ^a   De Berardis, Domenico ^a   Evangelista, Pina ^a   Costantini, Paola ^a   Orsini, Antonio ^a   Rossi, Alessandro ^b   Maggio, Roberto ^b  

^a ASL Teramo   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Antipsychotic; Dementia; Mortality

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; CHOLINESTERASE INHIBITOR; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DIAGNOSIS RELATED GROUP; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG USE; FEMALE; FOLLOW UP; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTPATIENT; RISK FACTOR; SURVIVAL RATE; VERY ELDERLY; ALZHEIMER DISEASE; EPIDEMIOLOGY; KAPLAN MEIER METHOD; RISK; STATISTICS AND NUMERICAL DATA;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CAUSALITY; CHOLINESTERASE INHIBITORS; DEMENTIA; DIBENZOTHIAZEPINES; FEMALE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; OUTPATIENTS; RISK; RISPERIDONE;

EID: 84896308512     PISSN: 00356484     EISSN: 20382502     Source Type: Journal    
DOI: 10.1708/1407.15623     Document Type: Article

References (33)

1. Trifirò G, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacol Res 2009; 59: 1-12.
2. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. JAMA 2002; 288: 1475-83.
3. Coen RF, Swanick GR, O'Boyle CA, Coakley D. Behavioral disturbance and other predictors of carer burden in Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12: 331-6. (Pubitemid 27148454)
4. Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998; 155: 1512-20. (Pubitemid 28512018)
5. Covinsky KE, Eng C, Lui LY, et al. Reduced employment in caregivers of frail elders: impact of ethnicity, patient clinical characteristics, and caregiver characteristics. J Gerontol A Biol Sci Med Sci 2001; 56: M707-13. (Pubitemid 33043481)
6. Wancata J, Windhaber J, Krautgartner M, Alexandrowicz R. The consequences of non-cognitive symptoms of dementia in medical hospital departments. Int J Psychiatr Med 2003; 33: 257-71. (Pubitemid 38351951)
7. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990; 147: 1049-51. (Pubitemid 20257519)
8. Kales HC, Chen PJ, Blow FC, Welsh DE, Mellow AM. Rates of clinical depression diagnosis, functional impairment and nursing home placement in coexisting dementia and depression. Am J Geriatr Psychiatry 2005; 13: 441-9.
9. Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioural and psychological symptoms of dementia in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry 2002; 17: 403-8.
10. Lopez OL, Becker JT, Sweet RA, et al. Patterns of change in the treatment of psychiatric symptoms in patients with probable Alzheimer's disease from 1983 to 2000. J Neuropsychiatry Clin Neurosci 2003; 15: 67-73. (Pubitemid 36168082)
11. Rapoport M, Mamdani M, Shulman KI, Herrmann N, Rochon PA. Antipsychotic use in the elderly: shifting trends and increasing costs. Int J Geriatr Psychiatry 2005; 20: 749-53. (Pubitemid 41158720)
12. Trifirò G, Sini G, Sturkenboom MC, et al. Prescribing pattern of antipsychotic drugs in the Italian general population 2000-2005: a focus on elderly with dementia. Int Clin Psychopharmacol 2010; 25: 22-8.
13. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomised double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60: 107-15. (Pubitemid 29104387)
14. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946-55. (Pubitemid 29442108)
15. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing home care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000; 57: 968-76.
16. Brodaty H, Ames D, Snowdon J, et al. A randomized, placebo controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: 134-43. (Pubitemid 36268315)
17. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19: 115-26. (Pubitemid 38247846)
18. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14: 191-210.
19. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355: 1525-38. (Pubitemid 44547805)
20. Wooltorton E. Risperidone: increased rate of cerebrovascular events in dementia. CMAJ 2002; 167: 1269-70. (Pubitemid 35370646)
21. Therapeutic Products Directorate: Risperdal (risperidone) and cerebrovascular adverse events in placebo-controlled dementia trials. Ottawa, Health Canada, Therapeutic Products Directorate, October 11, 2002. http://www.hc-sc.gc.ca/dhp-mps/alt-formats/hpfb-dgpsa/pdf/medeff/ risperdal-hpc-cps-eng.pdf [accessed December 4, 2012].
22. Kales HC, Valenstein M, Kim HM, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 2007; 164: 1568-76. (Pubitemid 350069737)
23. Medicines and Healthcare Products Regulatory Agency: Summary of clinical trial data on cerebrovascular adverse events (CVAEs)) in randomised clinical trials of risperidone conducted in patients with dementia. London: Department of Health, Medicines and Healthcare Products Regulatory Agency, March 9, 2004. http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con019490. pdf [accessed December 4, 2012].
24. Food and Drug Administration. FDA Public Health Advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances. Washington: FDA, April 11, 2005. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171. htm [accessed December 4, 2012].
25. Agenzia Italiana del Farmaco (AIFA). Il trattamento farmacologico dei disturbi psicotici in pazienti affetti da demenza. http://www.agenziafarmaco. gov.it/it/content/il-trattamento-farmacologico-dei-disturbi-psicotici-nei- pazienti-affetti-da-demenza-%E2%80%93-second [accessed December 4, 2012].
26. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH. Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med 2005; 353: 2335-41. (Pubitemid 41713745)
27. Rossi A, Maggio R, Riccardi I, Allegrini F, Stratta P. A quantitative analysis of antidepressant and antipsychotic prescriptions after an earthquake in Italy. J Trauma Stress 2011; 24: 129-32.
28. Schneeweiss S, Setoguchi S, Brookhart MA, Kaci L, Wang PS. Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data. CNS Drugs 2009; 23: 171-80.
29. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007; 176: 627-32. (Pubitemid 46426056)
30. Sacchetti E, Trifirò G, Caputi A, Turrina C, Spina E, Cricelli C. Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. J Psychopharmacol 2008; 22: 39-46.
31. Silvano E, Millan MJ, Mannoury la Cour C, et al. The tetrahydorisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors. Mol Pharmacol 2010; 78: 925-34.
32. Millan MJ, Mannoury la Cour C, et al. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano- 1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl] phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. J Pharmacol Exp Ther 2008; 324: 587-99. (Pubitemid 351185866)
33. Novi F, Millan MJ, Corsini GU, Maggio R. Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D2L receptors are modified by co-transfection of D3 receptors: potential role of heterodimer formation. J Neurochem 2007; 102: 1410-24. (Pubitemid 47174247)